118 results on '"Vaishnaw, Akshay K."'
Search Results
2. Association of the transthyretin variant V122I with polyneuropathy among individuals of African ancestry
3. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
4. Supplementary Tables from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
5. Supplementary Figures from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
6. Data from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
7. Supplementary Methods and Legends from First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
8. Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
9. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
10. Supplement to: Safety and efficacy of RNAi therapy for transthyretin amyloidosis.
11. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)
12. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
13. Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
14. Association of the transthyretin variant V122I with polyneuropathy among individuals of African descent
15. The V122I Variant in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy
16. Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects
17. DNase I hypersensitivity mapping and promoter polymorphism analysis of human C4
18. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity
19. Treatment of Psoriasis With Alefacept: Correlation of Clinical Improvement With Reductions of Memory T-Cell Counts
20. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study
21. Alefacept Treatment in Psoriatic Arthritis: Reduction of the Effector T Cell Population in Peripheral Blood and Synovial Tissue Is Associated With Improvement of Clinical Signs of Arthritis
22. CD4 + T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study
23. THE SPECTRUM OF APOPTOTIC DEFECTS AND CLINICAL MANIFESTATIONS, INCLUDING SYSTEMIC LUPUS ERYTHEMATOSUS, IN HUMANS WITH CD95 (Fas/APO-1) MUTATIONS
24. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations
25. Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
26. APOPTOSIS IN THE RHEUMATIC DISEASES
27. The Canale-Smith Syndrome
28. Homozygous Hereditary C1q Deficiency and Systemic Lupus Erythematosus: A New Family and the Molecular Basis of C1q Deficiency in Three Families
29. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis
30. Single‐Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N‐acetylgalactosamine–Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects.
31. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1
32. The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
33. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
34. US immigration order strikes against biotech
35. CD4+ T-cell–directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study
36. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis
37. The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus
38. Alefacept treatment in psoriatic arthritis - Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis
39. First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
40. A status report on RNAi therapeutics
41. Antibody responses to bacteriophage X174 and tetanus toxoid are normal in patients receiving alefacept (human LFA-3/IgG1 fusion protein)
42. Alefacept selectively reduces memory-effector (CD45RO+) T cells and improves clinical outcomes in psoriasis and psoriatic arthritis
43. Alefacept (human LFA-3/IgG1 fusion protein) is non-immunogenic in two randomized, placebo-controlled phase III trials for chronic plaque psoriasis
44. Structure and Function of Fas/Fas Ligand
45. Alefacept selectively reduces memory-effector (CD45RO+) T cells and improves clinical outcomes in psoriasis and psoriatic arthritis
46. [Untitled]
47. Regulation of Transcription of the TATA-less Human Complement Component C4 Gene
48. FasGene Mutations in the Canale–Smith Syndrome, an Inherited Lymphoproliferative Disorder Associated with Autoimmunity
49. Fas Gene Mutations in the Canale–Smith Syndrome, an Inherited Lymphoproliferative Disorder Associated with Autoimmunity.
50. Alefacept (human LFA-3/IgG1fusion protein) is non-immunogenic in two randomized, placebo-controlled phase III trials for chronic plaque psoriasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.